Program
admilparant
Also written as “BMS-986278”, “Admilparant” and “BMS-986278 Batched method, Dose B”.
Its studies are mostly in Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis · Kidney Failure, Chronic · Liver Diseases, led by Bristol-Myers Squibb.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 183 open or running | phase 3since Aug 15, 2023 | Feb 5, 2018 | Dec 27, 2027phase 3 · NCT06025578 |
- Named in Bristol-Myers Squibb’s own pipeline as
admilparant
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Feb 5, 2018.
- May 21, 2019Phase 1 study in Idiopathic Pulmonary FibrosisNCT03981094 · 22 enrolled · United States
- Mar 12, 2020Phase 2 study in Pulmonary FibrosisNCT04308681 · 403 enrolled · United States, Argentina, Australia and more
- Jul 9, 2020Phase 1 study in Healthy ParticipantsNCT04468815 · 24 enrolled · United States
- Sep 24, 2020Phase 1 study in Healthy VolunteersNCT04567667 · 9 enrolled · United States
- Dec 20, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT05684289 · 61 enrolled · United States
- Mar 28, 2023Phase 1 study in Healthy VolunteersNCT05805904 · 24 enrolled · China
- Aug 15, 20232 phase 3 studiesNCT06003426, NCT06025578
- May 17, 2024Phase 1 study in Liver DiseasesNCT06425198 · 37 enrolled · United States
- Aug 21, 2024Phase 1 study in Healthy ParticipantsNCT06568458 · 71 enrolled · United States
- Nov 28, 2024Phase 1 study in Healthy VolunteersNCT06715683 · 48 enrolled · United States
- Dec 4, 20242 phase 1 studiesNCT06723535, NCT06746402
- Nov 4, 2025Phase 1 study in Healthy ParticipantsNCT07225647 · 56 enrolled · United States
- Feb 12, 2026Phase 1 study in Healthy VolunteersNCT07422298 · 32 enrolled · United States
- Feb 25, 2026Phase 3 study in Pulmonary FibrosisNCT07441408 · 2,380 planned · United States, Argentina, Australia and more
Ahead
- Dec 27, 2027Primary completion: phase 3 study in Pulmonary FibrosisNCT06025578
- Nov 22, 2029Primary completion: phase 3 study in Pulmonary FibrosisNCT07441408
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07441408Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Not yet recruiting | Nov 22, 2029 | 2,380 |
| NCT07422298Healthy Volunteers · United States | 1 | Completed | Jun 14, 2026 | 32 |
| NCT07225647Healthy Participants · United States | 1 | Completed | Jan 5, 2026 | 56 |
| NCT06746402Healthy Volunteers · United States | 1 | Completed | Sep 11, 2025 | 42 |
| NCT06723535Kidney Failure, Chronic · United States | 1 | Completed | Sep 16, 2025 | 27 |
| NCT06715683Healthy Volunteers · United States | 1 | Completed | Mar 16, 2025 | 48 |
| NCT06568458Healthy Participants · United States | 1 | Completed | Feb 27, 2025 | 71 |
| NCT06425198Liver Diseases · United States | 1 | Completed | Dec 30, 2024 | 37 |
| NCT06025578Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 27, 2027 | 1,057 |
| NCT06003426Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 6, 2026 | 1,255 |
| NCT05805904Healthy Volunteers · China | 1 | Completed | May 23, 2023 | 24 |
| NCT05684289Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | May 2, 2023 | 61 |
| NCT04567667Healthy Volunteers · United States | 1 | Completed | Apr 11, 2021 | 9 |
| NCT04468815Healthy Participants · United States | 1 | Completed | Oct 7, 2020 | 24 |
| NCT04308681Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Completed | Aug 4, 2022 | 403 |
| NCT03981094Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | Jul 27, 2019 | 22 |
| NCT03712540Healthy Participants · United States | 1 | Completed | Nov 8, 2018 | 39 |
| NCT03429933Healthy Participants · Netherlands, United Kingdom | 1 | Completed | Mar 2, 2019 | 112 |
How it is read
Names in the registry
- “BMS-986278”, 13 entries
- “Admilparant”, 1 entry
- “BMS-986278 Batched method, Dose B”, 1 entry
- “BMS-986278 Continuous method”, 1 entry
- “BMS 986278”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Fibrosis, 3 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Kidney Failure, Chronic, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.